Abstract:Hepatic insulin resistance is associated with metabolic disorders such as type 2 diabetes (T2D), which often develops after the accumulation of lipids in the liver. In particular, elevated plasma levels of free fatty acids (FFA) are the primary sources of hepatic lipid accumulation that contributes to the development of insulin-resistant states. Interestingly, one gut-derived incretin hormone receptor called glucagon-like peptide 1 (GLP-1) receptor, is highly expressed on human hepatocytes. Although GLP-1-based therapies have shown great benefit in the treatment of T2D with improved glycemic control, they also additionally possess extrapancreatic metabolic actions including that in the liver. Studies have demonstrated that GLP-1 receptor agonist (GLP-1 RA) may reverse the progression of nonalcoholic fatty liver disease (NAFLD), a T2D-related disorder characterized by hepatic lipid accumulation. This suggests GLP-1 RA may be effective treatment options for NAFLD and associated hepatic disorders, but the mechanism behind this is still unknown. In the present study, we investigated the function of GLP-1 signaling in protecting human HepG2 hepatocytes from FFA-related damages. By using high-content analysis (HCA) cellomics techniques, we found that treatment with the GLP-1 RA liraglutide has shown a significant lipid droplets-lowering effect in hepatocytes exposure to high levels of FFAs. Liraglutide also decreased free radical generation and subsequently reduced oxidative stress, thus alleviated FFA induced inflammation. Moreover, activation of AMPK by liraglutide increased insulin sensitivity and improved oxidative stress-induced senescence by inducing Sirt1 pathway. Collectively, our results demonstrated that hepatic GLP-1 signaling may play a crucial role in the regulation of lipid deposits and related disorders in liver. This suggests the potential therapeutic usage of GLP-1 RA-based strategies for patients with T2D who also have NAFLD. Disclosure C. Huang: None. H. Li: None. C. Peng: None. E. Kornelius: None. Y. Yang: None. L. Chiu: None. C. Lin: None. Funding Ministry of Science and Technology of Taiwan (108-2314-B-040-021-MY3)

Glucagon-like peptide-1 contributes to increases ABCA1 expression by downregulating miR-758 to regulate cholesterol homeostasis.

Glucagon-Like Peptide-1 Modulates Cholesterol Homeostasis by Suppressing the miR-19b-Induced Downregulation of ABCA1.

GLP-1-Induced AMPK Activation Inhibits PARP-1 and Promotes LXR-Mediated ABCA1 Expression to Protect Pancreatic Β-Cells Against Cholesterol-Induced Toxicity Through Cholesterol Efflux

Glucagon-like peptide-1 analog-mediated protection against cholesterol-induced apoptosis via mammalian target of rapamycin activation in pancreatic βTC-6 cells -1mTORβTC-6.

Glucagon-Like Peptide-1 Analog-Mediated Protection Against Cholesterol-Induced Apoptosis Via Mammalian Target Of Rapamycin Activation In Pancreatic Beta Tc-6 Cells

Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes

Glucagon-like peptide-1 receptor mediates the improvement in glycolipid metabolism disorder via AKT and AMPK signalling pathways in L02 cells with insulin resistance

GLP-1RA Improves Diabetic Renal Injury by Alleviating Glomerular Endothelial Cells Pyrotosis Via RXRα/circ8411/miR-23a-5p/ABCA1 Pathway

Aberrant activation of liver X receptors impairs pancreatic beta cell function through upregulation of sterol regulatory element-binding protein 1c in mouse islets and rodent cell lines

Pharmacological Effects of EGLP-1, a Novel Analog of Glucagon-Like Peptide-1, on Carbohydrate and Lipid Metabolism

Glucagon-like Peptide 1 Regulates Adipogenesis in 3T3-L1 Preadipocytes

TGF-&beta;1 Up-Regulates Expression of ABCA1, ABCG1 and SR-BI Through Liver X Receptor &alpha; Signaling Pathway in THP-1 Macrophage-Derived Foam Cells

Effect of high glucose on the expression of liver X receptors and ABCA1 in human THP-1 macrophages

EGCG upregulated ABCA1 expression by decreasing miR-33 a generation to reduce lipid accumulation of macrophage-derived foam cells

The Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists as Novel Diabetes Drugs Are Mediated via the Suppression of miR-203a-3p and miR-429 Expression

Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism

Effects of Troglitazone on ATP Binding Cassette Transporter A1 Expression and Cholesterol Efflux in THP-1 Macrophage- derived Foam Cells-derived Foam Cells

1751-P: Induction of Sirt1-AMPK Pathway by GLP-1RA Liraglutide Reduces Hepatic Lipid Accumulation and Insulin Resistance

Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE–/– Mice

Glucagon-like Peptide 1 Protects Microvascular Endothelial Cells by Inactivating the PARP-1/iNOS/NO Pathway.

Exendin-4 Ameliorates Lipotoxicity-induced Glomerular Endothelial Cell Injury by Improving ABC Transporter A1-mediated Cholesterol Efflux in Diabetic Apoe Knockout Mice